Looking to speculate in biopharma stocks? Cramer's done some homework and he likes this one.
While the S&P 500 has climbed 11.75 percent in the past three months, the health care sector has only managed to muster a 2.3 percent climb over the same time period. But underperformance tends to be cyclical.
Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.
The "Mad Money" host says a shift in drug addiction makes this biopharma stock a screaming buy.
Richard Pops, Alkermes CEO, says it's a good time to be developing new medicines if you have access to capital. "Biotech industry is the lifeblood-- the wells spring-- of new innovation for the big pharmaceutical companies," he says.
Take a look at some of Thursday's morning movers:
The "Mad Money" host learns more about this biotechnology company, which he thinks is a great speculative stock.
Richard Pops, Alkermes CEO, discusses getting FDA approval for developing better drugs, with Mad Money's Cramer.
Stocks cut most of their earlier losses, but still finished in negative territory Monday as ongoing worries over the euro zone debt crisis kept investors from fully jumping in.
Stock index futures slumped Monday, tracking losses in Europe and Asia, amid renewed worries over a second bailout package for Greece.
Take a look at some of Monday morning's early movers:
Alkermes expects FDA approval for its new diabetes drug this month, but that might not be enough to make the stock worth buying, trader Guy Adami said.
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.
Jim Cramer’s researcher, Nicole Urken, looks into the big gain on Pharmasset and highlights some other well-positioned biotechs.
Cramer makes the call on viewers' favorite stocks.
Alkermes' CEO Richard Pops tells Cramer why the company is successful, and where it is going.
Markets are upbeat about the drug company's new diabetes drug and its recent European approval, with Richard Pops, Alkermes chairman/CEO.
See what's happening, who's talking and what will be making headlines on Monday's Squawk on the Street.
When speculating on stocks, the "Mad Money" host recommends following this rule.
The Fast Money traders are putting Alkermes on the radar after the firm’s latest clinical trials produced some very promising results.